Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, June 9, 2015

Public edition |

Newswise Cancer Research Wire for 09-Jun-2015

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

New MRI Approach Detects Early Liver Tumors in Mouse Model of Human Disease

Scientists at Georgia State University (GSU) with funding from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) have designed an imaging technique to detect early-stage liver tumors, and have proven it successful in mice. Their study in an animal model is an essential step toward creating tools to improve liver tumor detection in human patients—whether primary liver cancer or metastatic tumors that arise in liver but have spread from other tissue.

 • Image(s) embedded • 

PNAS, May-2015

– National Institute of Biomedical Imaging and Bioengineering

Disrupting Tumor Cell "Microenvironment" Suggests a New Way to Treat a Prevalent Childhood Leukemia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade.

(Embargo expired on 08-Jun-2015 at 12:00 ET)

Cancer Cell

– NYU Langone Medical Center

Certain Donors with High T Cell Counts Make a Better Match for Stem-Cell Transplant Patients, Penn Study Suggests

Older patients who received stem cells from younger, unrelated donors with higher numbers of so-called killer T cells (CD8 cells) had significantly reduced risk of disease relapse and improved survival compared to those who received stem-cells from donors with low numbers of CD8 cells, including older matched siblings.

(Embargo expired on 08-Jun-2015 at 16:00 ET)

Journal of Clinical Oncology

– Perelman School of Medicine at the University of Pennsylvania

Scripps Florida Scientists Show Antitumor Agent Can Be Activated by Natural Response to Cell Stress

Scientists from the Florida campus of The Scripps Research Institute have found that a drug candidate with anticancer potential can be activated by one of the body’s natural responses to cellular stress. Once activated, the agent can kill prostate cancer cells.

 • Image(s) embedded •  (Embargo expired on 08-Jun-2015 at 15:00 ET)

Proceedings of the National Academy of Sciences

– Scripps Research Institute

Yin and Yang: Immune Signaling Protein Has Opposing Roles in Breast Cancer Development

Countering previously held beliefs, researchers at The University of Texas MD Anderson Cancer Center have discovered that inhibiting the immune receptor protein TLR4 may not be a wise treatment strategy in all cancers.

 • Image(s) embedded •  (Embargo expired on 08-Jun-2015 at 15:00 ET)

Proceedings of the National Academy of Sciences

– University of Texas M. D. Anderson Cancer Center

Texas Tech Researchers Develop Models For Targeted Cancer Therapy

The results of a recent study on targeted therapy of a specific type of brain cancer were published by Nature Medicine showing specific progress in cancer treatment.

Nature Medicine

– Texas Tech University

Study Supports Early Intervention for Prostate Cancer Patients Who Experience Significant Emotional Distress

A study led by the University at Buffalo and Roswell Park Cancer Institute has identified beliefs and personality traits that are associated with higher levels of distress in newly diagnosed prostate cancer patients.


– University at Buffalo

Trending Stories Report for 8 June 2015

Trending news releases with the most views in a single day. Topics include: marijuana exposure in children, female viagra, botox for nerve pain, genetics, cancer and bone marrow transplants, stroke, dengue fever, and memory loss in epilepsy.

– Newswise Trends

Chemo Instead of Hormone Therapy May Be Preferred Option for Some with Advanced Prostate Cancer

In a small clinical trial, scientists at Johns Hopkins’ Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

JAMA Oncology; W81XWH-12-1-0605; P50 CA058236; P30 CA006973

– Johns Hopkins Medicine

Novel Approaches Using Targeted Immunotherapeutics Help Older Patients Undergoing Bone Marrow Transplantations

Bone marrow transplant and hematology specialist Hillard M. Lazarus, MD, Professor of Medicine at Case Western Reserve University (CWRU) School of Medicine

 • Video / Image(s) embedded • 

– Actinium Pharmaceuticals, Inc.

Fruit Fly Genetics Reveal Pesticide Resistance and Insight Into Cancer

Thomas Werner, an assistant professor of biological sciences at Michigan Tech, has bridged the miniscule and the massive in an effort to better understand the mechanisms behind several unique features of fruit fly genes.

 • Image(s) embedded • 

PLoS ONE, June-2015; PNAS, June-2015; Nature Education

– Michigan Technological University

Rabbit Virus Improves Bone Marrow Transplants, Kills Some Cancer Cells

University of Florida Health researchers have discovered that a rabbit virus can deliver a one-two punch, killing some kinds of cancer cells while eliminating a common and dangerous complication of bone marrow transplants.

– University of Florida

Additional Research Using Novel Cell Encapsulation Technology Pushes Forward in the Treatment of Malignant Ascites

A preclinical study is set to determining the effectiveness of its Cell-in-a-Box(R) live-cell encapsulation technology together with the anticancer drug, ifosfamide, in slowing the accumulation of fluid in the abdomen that accompanies the growth of pancreatic and other abdominal cancerous tumors.

 • Video embedded • 

– PharmaCyte

Wistar Scientists Discover “Highly Effective” New Biomarker for Lung Cancer

Scientists at The Wistar Institute have found a protein that circulates in the blood that appears to be more accurate at detecting non-small cell lung cancer (NSCLC) than currently available methods used for screening.

Oncotarget, May-2015

– Wistar Institute

Triple Treatment Keeps Cancer From Coming Back

Lung cancer, the world’s deadliest cancer, can be apparently successfully treated, only to return. And when it does so, it’s often resistant to the drugs that worked the first time. Now, a team led by Prof. Yosef Yarden has devised a novel three-pronged strategy that, in mice, kept lung cancer cells from developing resistance in the first place.

 • Image(s) embedded • 

Science Signaling, June 3, 2015

– Weizmann Institute of Science

Trending Stories Report for 3 June 2015

Trending news releases with the most views in a single day. Topics include: aging & genetics, cancer, treatment for kidney disease, healthcare & wellbeing, environment, welcoming new leaders.

– Newswise Trends

Homing in on What's Wearing Out T Cells

When the T cells of your immune system are forced to deal over time with cancer or a chronic infection they become exhausted - less effective at attacking and destroying invaders. While the PD-1 protein pathway has long been implicated as a primary player in T cell exhaustion, a major question has been whether PD-1 actually directly causes exhaustion. A new paper seems to, at least partially, let PD-1 off the hook.

Journal of Experimental Medicine<; AI105343, AI112521, AI117718, AI082630, AI095608, HHSN266200500030C

– Perelman School of Medicine at the University of Pennsylvania

Condensin II Complex Is “Master Controller” Behind DNA Structure Reorganization During Senescence

Wistar Institute scientists have identified how a specific variant of a key protein complex found in human cells called condensin can reorganize a cell’s genetic architecture in such a way as to promote senescence, making it an important facilitator in a cell’s anticancer ability.

 • Image(s) embedded • 

W.W. Smith Charitable Trust; V Foundation; Edward Mallinckrodt Jr. Foundation; (CCSG) CA010815

– Wistar Institute

Policy and Public Affairs

Panel Recommends Improvements in Estrogen Testing Accuracy

Unreliable estrogen measurements have had a negative impact on the treatment of and research into many hormone-related cancers and chronic conditions. To improve patient care, a panel of medical experts has called for accurate, standardized estrogen testing methods in a statement published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).

Journal of Clinical Endocrinology & Metabolism, June-2015

– Endocrine Society


Maximize Opportunities to Provide Best Practice Cancer Care with HOPA Oncology Pharmacy Practice Management Program September 18-19, 2015- Rosemont, IL

The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O’Hare on September 18-19, 2015, in Rosemont, IL. The program will examine how to provide a high level of clinical practice when patients demand more, but front offices and third-party payers require it be done with less.

– Hematology Oncology Pharmacy Association

NCCN Collaborates with Pfizer to Improve Provider Performance and Quality in Treatment of Metastatic Breast Cancer

NCCN and Pfizer will elicit grant proposals for quality improvement and education in metastatic breast cancer.

– National Comprehensive Cancer Network® (NCCN®)

UNM Cancer Center Scientist Elected to National Steering Committee

Anita Kinney, PhD, RN, at the University of New Mexico Cancer Center, has been elected to the National Cancer Institute’s Cancer Care Delivery Research Steering Committee. The newly formed committee will guide nationwide research that studies how people get their cancer care and how well they fare as a result of it.

– University of New Mexico Cancer Center

subscribe/unsubscribe :: edit my preferences
© 2015 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us